98%
921
2 minutes
20
Chronic lung allograft dysfunction (CLAD) is the major cause of death after lung transplantation. Angiotensin II (AngII), the main effector of the renin-angiotensin system, elicits fibrosis in both kidney and lung. We identified six AngII-regulated proteins (Ras homolog family member B (RHOB), bone marrow stromal cell antigen 1 (BST1), lysophospholipase 1 (LYPA1), glutamine synthetase (GLNA), thrombospondin 1 (TSP1) and laminin subunit β2 (LAMB2)) that were increased in urine of patients with kidney allograft fibrosis. We hypothesised that the renin-angiotensin system is active in CLAD and that AngII-regulated proteins are increased in bronchoalveolar lavage fluid (BAL) of CLAD patients.We performed immunostaining of AngII receptors (AGTR1 and AGTR2), TSP1 and GLNA in 10 CLAD lungs and five controls. Using mass spectrometry, we quantified peptides corresponding to AngII-regulated proteins in BAL of 40 lung transplant recipients (stable, acute lung allograft dysfunction (ALAD) and CLAD). Machine learning algorithms were developed to predict CLAD based on BAL peptide concentrations.Immunostaining demonstrated significantly more AGTR1 cells in CLAD control lungs (p=0.02). TSP1 and GLNA immunostaining positively correlated with the degree of lung fibrosis (R=0.42 and 0.57, respectively). In BAL, we noted a trend towards higher concentrations of AngII-regulated peptides in patients with CLAD at the time of bronchoscopy, and significantly higher concentrations of BST1, GLNA and RHOB peptides in patients that developed CLAD at follow-up (p<0.05). The support vector machine classifier discriminated CLAD from stable and ALAD patients at the time of bronchoscopy (area under the curve (AUC) 0.86) and accurately predicted subsequent CLAD development (AUC 0.97).Proteins involved in the renin-angiotensin system are increased in CLAD lungs and BAL. AngII-regulated peptides measured in BAL may accurately identify patients with CLAD and predict subsequent CLAD development.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1183/13993003.02975-2020 | DOI Listing |
Pediatr Nephrol
September 2025
Pediatric Nephrology Department, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain.
Copeptin, a stable glycopeptide derived from the precursor of arginine vasopressin (AVP), has emerged as a valuable surrogate biomarker for AVP due to its stability and ease of measurement. This narrative review explores the physiological role of copeptin, its utility as a diagnostic and prognostic biomarker in different kidney diseases, and its clinical relevance in renal tubular disorders. The clinical application of copeptin as a diagnostic biomarker is best established in the differential diagnosis of polyuria-polydipsia syndrome (PPS), distinguishing nephrogenic diabetes insipidus (NDI) from central diabetes insipidus (CDI) and primary polydipsia (PP).
View Article and Find Full Text PDFAnn Med
December 2025
Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China.
Purpose: End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and delay the progression of chronic kidney disease. We aim to perform a comprehensive analysis of current clinical evidence on the use of sacubitril/valsartan in ESRD patients.
View Article and Find Full Text PDFClin Exp Nephrol
September 2025
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Background: Sacubitril/valsartan is typically prescribed for patients with heart failure and hypertension. We previously reported that sacubitril/valsartan provides comparable blood pressure (BP) reduction and superior tolerability compared to thiazide diuretics. This post hoc study aimed to compare the effects of sacubitril/valsartan and thiazide diuretics in patients with chronic kidney disease (CKD).
View Article and Find Full Text PDFPalliat Med Rep
August 2025
Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society (NVS), Karolinska Institutet, Huddinge, Sweden.
Background: Treatment with antihypertensives in patients with advanced cancer is often continued until very late in the disease trajectory, despite a considerable risk of hypotension.
Objectives: The aim of this study was to investigate the time of deprescribing of antihypertensive agents in patients with cancer receiving palliative care during their last year of life. The monitoring of blood pressure (BP) during treatment was also studied.
J Prim Care Community Health
September 2025
Division of Nephrology, Department of Medicine, National University Hospital, Singapore.
Background: Chronic kidney disease (CKD) management was largely centered around renin-angiotensin-aldosterone system inhibitors (RAASi) optimization, until recent emergence of novel therapeutics. However, slow adoption of guideline-directed therapy leaves patients vulnerable to disease progression. In 2022, a data-driven informatics approach was introduced to track real-time adherence to best practices.
View Article and Find Full Text PDF